| Trial ID: | L0035 |
| Source ID: | NCT04031729
|
| Associated Drug: |
Aspirin
|
| Title: |
Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Fatty Liver|Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: Aspirin 81 mg|Drug: Placebo oral tablet
|
| Outcome Measures: |
Percent intrahepatic lipid content, quantified by 1H-MRS|Concentrations of circulating bioactive lipid mediators
|
| Sponsor/Collaborators: |
Massachusetts General Hospital
|
| Gender: |
All
|
| Age: |
18 Years to 69 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1/Phase 2
|
| Enrollment: |
80
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
September 12, 2019
|
| Completion Date: |
September 2024
|
| Results First Posted: |
--
|
| Last Update Posted: |
February 24, 2022
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04031729
|
